Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 25M | 22M | 13M | 6M | 2M |
| Gross Profit | 9M | 7M | 6M | 2M | 786K |
| Operating Income | -972K | -2M | -800K | -2M | -7M |
| EBITDA | -11M | -1M | 560K | -1M | -7M |
| Net Income | -13M | -4M | -4M | -3M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.007
+0.00% today
1Y Change
-81.48%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Adastra Holdings Ltd. (XTXXF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 81.5% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +11.8%, EPS growth of -3628.3%, a dividend yield of 0.0%. What stands out right now is revenue +11.8%, EPS -3628.3%, free cash flow -65.3% with operating margin -14.4% and ROIC -89.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XTXXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XTXXF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XTXXF Max Drawdown
-98.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XTXXF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.5M
-55.6% YoY
FY Net Income
-$7.6M
-176.9% YoY
Free Cash Flow
-$4.6M
-183.4% YoY
Revenue Growth
+11.8%
EPS Growth
-3628.3%
Gross Margin
32.3%
Net Margin
-85.9%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 25M | 22M | 13M | 6M | 2M |
| Gross Profit | 9M | 7M | 6M | 2M | 786K |
| Operating Income | -972K | -2M | -800K | -2M | -7M |
| EBITDA | -11M | -1M | 560K | -1M | -7M |
| Net Income | -13M | -4M | -4M | -3M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 1M | 1M | 745K | 1M |
| Total Assets | 19M | 32M | 32M | 29M | 14M |
| Total Liabilities | 18M | 18M | 14M | 6M | 4M |
| Shareholder Equity | 1M | 15M | 18M | 22M | 10M |
| Total Debt | 4M | 4M | 4M | 4M | 3M |
| Net Debt | 2M | 2M | 3M | 3M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
-168.8% YoY
Capital Expenditures
2M
-209.9% YoY
Free Cash Flow
5M
-183.4% YoY
Key ratios
Gross Margin
32.3%
Operating Margin
-14.4%
Net Margin
-85.9%
ROE
-6086.9%
Debt / Equity
-3.77x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.